Upadacitinib has become an alternative therapy for multiple inflammatory indications such as moderate-to-severe rheumatoid arthritis, ankylosing spondylitis, non-radiographic axial spondylarthritis, ulcerative colitis, psoriatic arthritis, and atopic dermatitis, whose patients either had an inadequate response or intolerance to one or more TNF blockers or other systemic therapy. The gene discussed is TNF; the disease is ulcerative colitis.